Angiopoietin-Tie2 signaling axis (Ang-Tie2 axis)

The Angiopoietin-Tie2 signaling axis is a fundamental regulator of vascular development, maturation, and stability, consisting of the receptor tyrosine kinase Tie2 (also known as TEK) and its primary ligands, Angiopoietin-1 (Ang1) and Angiopoietin-2 (Ang2). Ang1 acts as a constitutive agonist that promotes endothelial cell survival and maintains vascular quiescence, while Ang2 typically functions as a context-dependent antagonist that destabilizes vessels to allow for remodeling or pathological angiogenesis, particularly in the presence of VEGF. Dysregulation of this axis, often characterized by elevated Ang2 levels, is a hallmark of various diseases including cancer, where it drives tumor angiogenesis, and retinal disorders like diabetic macular edema, where it contributes to vascular leakage. Therapeutic strategies targeting this axis include Ang2-neutralizing antibodies, bispecific molecules targeting both Ang2 and VEGF, and Tie2 activators. These therapies aim to restore vascular integrity and inhibit pathological vessel growth, offering a complementary approach to traditional anti-VEGF treatments.

Other names

Angiopoietin-1/Angiopoietin-2 – Tie2 receptor signaling axisAng-Tie2 pathwayTEK signaling axisAngiopoietin-TEK signaling pathway

Therapeutic agents targeting this axis function by neutralizing Angiopoietin-2 to prevent vascular destabilization, activating the Tie2 receptor to enhance endothelial stability, or utilizing bispecific formats to simultaneously inhibit Angiopoietin-2 and VEGF-A, thereby reducing pathological neovascularization and vascular leakage.